Literature DB >> 33634974

MiR-378a-3p as a putative biomarker for hepatocellular carcinoma diagnosis and prognosis: Computational screening with experimental validation.

Fuliang Qian1, Jinghan Wang2, Ying Wang2, Qian Gao3, Wenying Yan1, Yuxin Lin3, Li Shen4, Yufeng Xie1,3, Xiaoqing Jiang2, Bairong Shen4.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a malignant disease with high morbidity and mortality, and the molecular mechanism for the genesis and progression is complex and heterogeneous. Biomarker discovery is crucial for the personalized and precision treatment of HCC. The accumulation of reported microRNA biomarkers makes it possible to combine computational identification with experimental validation to accelerate the discovery of novel biomarker.
RESULTS: In the present work, we applied a rational computer-aided biomarker discovery model to screen for the HCC diagnosis biomarker. Two HCC-associated networks were constructed based on the microRNA and mRNA expression profiles, and the potential microRNA biomarkers were identified based on their unique regulatory and influential power in the network. These putative biomarkers were then experimentally validated. One prominent example among these identified biomarkers is MiR-378a-3p: It was shown to independently regulate several important transcription factors such as PLAGL2 and β-catenin, affecting the β-catenin signaling. Such mechanism may indicate a potential tumor suppressor role of MiR-378a-3p and the impact of its abnormal expression on the cell growth and invasion of HCC.
CONCLUSIONS: A bioinformatics model with network topological and functional characterization was successfully applied to the identification of HCC biomarkers. The predicted microRNA biomarkers were than validated with experiments using human HCC cell lines, model animal, and clinical specimens. The results confirmed the prediction by our proposed model that miR-378a-3p was a putative biomarker for diagnosis and prognosis of HCC.
© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Entities:  

Keywords:  cancer genesis and progression; hepatocellular carcinoma (HCC); microRNA biomarker; network structure characterization; unique regulatory and influential power

Mesh:

Substances:

Year:  2021        PMID: 33634974      PMCID: PMC7882078          DOI: 10.1002/ctm2.307

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN: 2001-1326


  69 in total

1.  Combinatorial microRNA target predictions.

Authors:  Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

2.  Clinical effects of miR-101 on prognosis of hepatocellular carcinoma and carcinogenic mechanism of anti-miR-101.

Authors:  Xuecheng Lv; Jinghua Li; Bingnan Yang
Journal:  Oncol Rep       Date:  2016-07-28       Impact factor: 3.906

3.  Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Authors:  Yun Xie; Qinwei Yao; Azeem Mehmood Butt; Jia Guo; Zhou Tian; Xuli Bao; Hongxia Li; Qinghua Meng; Jun Lu
Journal:  Cancer Biol Ther       Date:  2014-06-27       Impact factor: 4.742

4.  Prioritizing candidate disease miRNAs by topological features in the miRNA target-dysregulated network: case study of prostate cancer.

Authors:  Juan Xu; Chuan-Xing Li; Jun-Ying Lv; Yong-Sheng Li; Yun Xiao; Ting-Ting Shao; Xiao Huo; Xiang Li; Yan Zou; Qing-Lian Han; Xia Li; Li-Hua Wang; Huan Ren
Journal:  Mol Cancer Ther       Date:  2011-07-18       Impact factor: 6.261

5.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.

Authors:  Stephanie Roessler; Hu-Liang Jia; Anuradha Budhu; Marshonna Forgues; Qing-Hai Ye; Ju-Seog Lee; Snorri S Thorgeirsson; Zhongtang Sun; Zhao-You Tang; Lun-Xiu Qin; Xin Wei Wang
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

6.  MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.

Authors:  Leibo Xu; Susanne Beckebaum; Speranta Iacob; Gang Wu; Gernot M Kaiser; Arnold Radtke; Chao Liu; Iyad Kabar; Hartmut H Schmidt; Xiaoyong Zhang; Mengji Lu; Vito R Cicinnati
Journal:  J Hepatol       Date:  2013-11-06       Impact factor: 25.083

7.  Most mammalian mRNAs are conserved targets of microRNAs.

Authors:  Robin C Friedman; Kyle Kai-How Farh; Christopher B Burge; David P Bartel
Journal:  Genome Res       Date:  2008-10-27       Impact factor: 9.043

8.  Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening.

Authors:  Lihua Li; Zijan Guo; Juanhua Wang; Yong Mao; Qi Gao
Journal:  Dig Dis Sci       Date:  2012-08-05       Impact factor: 3.199

9.  Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma.

Authors:  Kazumoto Murata; Atsushi Sakamoto
Journal:  Int J Oncol       Date:  2008-12       Impact factor: 5.650

10.  Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets.

Authors:  Fang Zheng; Yi-Ji Liao; Mu-Yan Cai; Tian-Hao Liu; Shu-Peng Chen; Pei-Hong Wu; Long Wu; Xiu-Wu Bian; Xin-Yuan Guan; Yi-Xin Zeng; Yun-Fei Yuan; Hsiang-Fu Kung; Dan Xie
Journal:  PLoS Genet       Date:  2015-02-18       Impact factor: 5.917

View more
  4 in total

1.  The fourth scientific discovery paradigm for precision medicine and healthcare: Challenges ahead.

Authors:  Li Shen; Jinwei Bai; Jiao Wang; Bairong Shen
Journal:  Precis Clin Med       Date:  2021-04-16

2.  Effects of microRNA-101-3p on predicting pediatric acute respiratory distress syndrome and its role in human alveolar epithelial cell.

Authors:  Fang Yin; Qi Li; Min Cao; Yaqin Duan; Liu Zhao; Lumin Gan; Zili Cai
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.

Authors:  Yaqin Li; Tao Zhou; Xianyi Cheng; Dezhi Li; Meng Zhao; Wei V Zheng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 4.  Current Perspectives on the Unique Roles of Exosomes in Drug Resistance of Hepatocellular Carcinoma.

Authors:  Dongdong Xue; Jingzhao Han; Ze Liang; Lin Jia; Yifan Liu; Hongfang Tuo; Yanhui Peng
Journal:  J Hepatocell Carcinoma       Date:  2022-02-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.